Minicircle DNA Vectors for Viral Vector Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional gene therapy methods using plasmid DNA vectors have lower transfection efficiency compared to viral vectors, and the production of viral vectors often involves unwanted sequences from plasmids, leading to regulatory issues and reduced efficiency due to 'retropackaging' where plasmid sequences are packaged into viral vectors.
Innovation Solution
The use of minicircles, which are small, circular DNA molecules containing a desired expression cassette with minimal unwanted prokaryotic sequences, for cotransfection to produce viral vectors, avoiding the packaging of unwanted sequences and improving biosafety and transgene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If plasmid DNA vectors are used for gene therapy, then the production process is simple, but the transfection efficiency is lower compared to viral vectors
Solution Approach 1:
The plasmid DNA is segmented into multiple separate plasmids, each carrying specific functions (transfer plasmid, packaging plasmid, helper plasmid). This segmentation allows optimization of each component's function while maintaining the overall production process, achieving high transfection efficiency through viral vector production without requiring complete plasmid replacement
Solution Approach 2:
Viral vectors serve as intermediaries between plasmid DNA and target cells. The plasmid DNA is first used to produce viral vectors in producer cells, which then serve as the actual transfection vehicles. This two-step intermediary process combines the ease of plasmid manufacturing with the high efficiency of viral transfection
2Reliability
If conventional plasmids are used for viral vector production, then the transfection efficiency is high, but unwanted plasmid sequences are packaged into viral vectors causing retropackaging
Solution Approach 1:
The packaging signals and replication origins are extracted from conventional plasmids and placed on separate packaging plasmids. The transfer plasmid contains only the essential transfer sequence flanked by ITRs, while packaging functions are provided in trans by separate plasmids. This extraction eliminates retropackaging of unwanted sequences while maintaining high transfection efficiency
Solution Approach 2:
The plasmid system is segmented into functionally separate components: transfer plasmid (with ITRs and transfer sequence), packaging plasmid (with packaging signals and replication origin), and helper plasmid (with helper functions). This functional segmentation prevents unwanted sequences from being packaged while maintaining viral vector production efficiency
3Reliability
If multiple plasmids are used for viral vector production, then the transfection efficiency improves, but the optimization of relative plasmid amounts becomes significantly more difficult
Solution Approach 1:
The system uses specific molar ratios of plasmids (e.g., 1:1:1 or optimized ratios of transfer:packaging:helper plasmids) to achieve optimal transfection efficiency. By establishing standardizable parameter ranges for plasmid amounts and ratios, the complexity of optimization is reduced while maintaining high transfection efficiency
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to a minicircle transfer vector for the production of viral vectors, comprising a transfer sequence and specific packaging signals on both sides of the transfer sequence for packaging the transfer sequence into particles of a viral vector. The invention also relates to minicircle packaging vectors that carry support functions for the production of viral vectors. Furthermore, the invention relates to cells carrying such minicircles. The invention also relates to methods for producing viral vectors using such minicircles and viral vectors obtained thereby, as well as kits useful in carrying out such methods.